The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
Open accessAbstract
CD8(+) T cells recognizing tumor-specific antigens are detected in cancer patients but are dysfunctional. Here we developed a tamoxifen-inducible liver cancer mouse model with a defined oncogenic driver antigen (SV40 large T-antigen) to follow the activation and differentiation of naive tumor-specific CD8(+) T (TST) cells after tumor initiation. Early during the pre-malignant phase of tumorigenesis, TST cells became dysfunctional, exhibiting phenotypic, functional, and transcriptional features similar to dysfunctional T cells isolated from late-stage human tumors. Thus, T cell dysfunction seen in advanced human cancers may already be established early during tumorigenesis. Although the TST cell dysfunctional state was initially therapeutically reversible, it ultimately evolved into a fixed state. Persistent antigen exposure rather than factors associated with the tumor microenvironment drove dysfunction. Moreover, the TST cell differentiation and dysfunction program exhibited features distinct from T cell exhaustion in chronic infections. Strategies to overcome this antigen-driven, cell-intrinsic dysfunction may be required to improve cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Profiling adoptively transferred SV40 large T cell antigen (Tag+)–specific CD8+ T cells indicated that Tag+ T cells followed classic signs of exhaustion upon entry into the tumor-bearing livers (fig. S2D) (19).”
From Bile acid synthesis impedes tumor-specific T cell responses during liver cancer (2025) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, terminal Tex (Ttex) cells accumulate over time and respond poorly to ICB therapies8,11–13.”
From Proteotoxic stress response drives T cell exhaustion and immune evasion (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredIn the citing paper
“Indeed, the T cell immune response to HCC antigens is reportedly dysfunctional and unreactive to HCC55.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“…studies have demonstrated that blocking inhibitory receptors (checkpoint blockade) can mediate functional rescue of unresponsive T cells in chronic infection or tumors (Barber et al., 2006; Brahmer et al., 2012; Perez-Gracia et al., 2014; (A) Tamoxifen (Tam)-inducible ASTxCre-ERT2 tumor model.”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
T cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252
Flagged first, then by citations
1 of the 60 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 726
TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion
Shakiba, M., Zumbo, P., Espinosa-Carrasco, G., Menocal, L., Dündar, F., Carson, S. E., Bruno, E. M., Rivera, F. J. S., Lowe, S. W., Camara, S., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201966 · Cited by 151
Self-citationDetecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation
Liu, Z., Li, J. P., Chen, M., Wu, M., Shi, Y., Li, W., Teijaro, J. R., & Wu, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.048 · Cited by 148
Hallmarks of Resistance to Immune-Checkpoint Inhibitors
Karasarides, M., Cogdill, A. P., Robbins, P. B., Bowden, M., Burton, E. M., Butterfield, L. H., Cesano, A., Hammer, C., Haymaker, C., Horak, C. E., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0586 · Cited by 154
Stock, S., Schmitt, M. W., & Sellner, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246223 · Cited by 146
Impact of risk factors on early cancer evolution
Weeden, C. E., Hill, W., Lim, E. L., Gronroos, E. C., & Swanton, C. (2023) · Cell · doi:10.1016/j.cell.2023.03.013 · Cited by 147
Pai, C.-C. S., Huang, J. T., Lu, X., Simons, D. M., Park, C., Chang, A., Tamaki, W., Liu, E., Roybal, K. T., Seagal, J., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.006 · Cited by 141
Tang, L., Wu, J., Li, C.-G., Jiang, H., Xu, M., Du, M., Yin, Z., Mei, H., & Hu, Y. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3003 · Cited by 140
Localization, tissue biology and T cell state — implications for cancer immunotherapy
Schenkel, J. M., & Pauken, K. E. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00884-8 · Cited by 144
T cell dysfunction and therapeutic intervention in cancer
Zebley, C. C., Zehn, D., Gottschalk, S. M., & Chi, H. (2024) · Nature Immunology · doi:10.1038/s41590-024-01896-9 · Cited by 145
Ogando, J., Sáez, M. E., Santos, J. V., Nuevo‐Tapioles, C., Gut, M., Esteve‐Codina, A., Heath, S. C., González‐Pérez, A., Cuezva, J. M., Lacalle, R. A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0628-7 · Cited by 137
The current state and future of T-cell exhaustion research
Jenkins, E. M., Whitehead, T., Fellermeyer, M., Davis, S. J., & Sharma, S. (2023) · Oxford Open Immunology · doi:10.1093/oxfimm/iqad006 · Cited by 153
Arcangeli, S., Falcone, L., Camisa, B., De Girardi, F., Biondi, M., Giglio, F., Ciceri, F., Bonini, C., Bondanza, A., & Casucci, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01217 · Cited by 134
Hanna, B. S., Cid, L. L., Iskar, M., Roessner, P. M., Klett, L. C., Wong, J., Paul, Y., Ioannou, N., Öztürk, S., Mack, N. L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.004 · Cited by 137
Rudloff, M. W., Zumbo, P., Favret, N. R., Roetman, J. J., Román, C. R. D., Erwin, M. M., Murray, K. A., Jonnakuti, S. T., Dündar, F., Betel, D., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01578-y · Cited by 135
Self-citationWnt Signaling in the Regulation of Immune Cell and Cancer Therapeutics
Haseeb, M., Pirzada, R. H., Ain, Q. U., & Choi, S. (2019) · Cells · doi:10.3390/cells8111380 · Cited by 136
Rejection of immunogenic tumor clones is limited by clonal fraction
Gejman, R. S., Chang, A. Y., Jones, H. F., DiKun, K. M., Hakimi, A. A., Schietinger, A., & Scheinberg, D. A. (2018) · eLife · doi:10.7554/elife.41090 · Cited by 127
Self-citationSpatially mapping the immune landscape of melanoma using imaging mass cytometry
Moldoveanu, D., Ramsay, L., Lajoie, M., Anderson-Trocmé, L., Lingrand, M., Berry, D., Perus, L. J. M., Wei, Y., Moraes, C., Alkallas, R., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abi5072 · Cited by 125
The tumor-draining lymph node as a reservoir for systemic immune surveillance
Delclaux, I., Ventre, K. S., Jones, D., & Lund, A. W. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.09.006 · Cited by 143
Liu, F., Qin, L., Liao, Z., Song, J., Yuan, C., Liu, Y., Wang, Y., Xu, H., Zhang, Q., Pei, Y., et al. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00165-3 · Cited by 130
Papavassiliou, A. G., & Musti, A. M. (2020) · Cells · doi:10.3390/cells9112470 · Cited by 124
T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control
Steele, M. M., Jaiswal, A., Delclaux, I., Dryg, I. D., Murugan, D., Femel, J., Son, S., du Bois, H., Hill, C. M., Leachman, S. A., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01443-y · Cited by 130
Connections Between Metabolism and Epigenetics in Programming Cellular Differentiation
Chisolm, D. A., & Weinmann, A. S. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053127 · Cited by 133
Potentiating adoptive cell therapy using synthetic IL-9 receptors
Kalbasi, A. K., Siurala, M., Su, L., Tariveranmoshabad, M., Picton, L. K., Ravikumar, P., Li, P., Lin, J., Escuin-Ordinas, H., Da, T., et al. (2022) · Nature · doi:10.1038/s41586-022-04801-2 · Cited by 121
Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections
Philip, M., & Schietinger, A. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.04.014 · Cited by 128
Self-citationInsights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 122
A unified atlas of CD8 T cell dysfunctional states in cancer and infection
Pritykin, Y., van der Veeken, J., Pine, A. R., Zhong, Y., Şahin, M., Mažutis, L., Pe’er, D., Rudensky, A. Y., & Leslie, C. S. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.045 · Cited by 117
Hu, S., Lu, H., Xie, W., Wang, D., Shan, Z., Xing, X., Wang, X.-M., Fang, J., Dong, W., Dai, W., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157649 · Cited by 129
Improving CAR T-Cell Persistence
Pietrobon, V., Todd, L. A., Goswami, A., Stefanson, O., Yang, Z., & Marincola, F. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910828 · Cited by 124
DNA hypermethylation during tuberculosis dampens host immune responsiveness
DiNardo, A. R., Rajapakshe, K., Nishiguchi, T., Mtetwa, G., Dlamini, Q., Kahari, J., Mahapatra, S., Kay, A., Gugu, M., Mace, E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134622 · Cited by 116
Ge, H., Mu, L., Jin, L., Yang, C., Chang, Y. E., Yu, L., DeLeon, G., Deleyrolle, L. P., Mitchell, D. A., Kubilis, P. S., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30830 · Cited by 109
Tantalo, D. G. M., Oliver, A. J., von Scheidt, B., Harrison, A. J., Mueller, S. N., Kershaw, M. H., & Slaney, C. Y. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002555 · Cited by 112
Bailey, S. R., Nelson, M. H., Majchrzak, K., Bowers, J. S., Wyatt, M. M., Smith, A. S., Neal, L. R., Shirai, K., Carpenito, C., June, C. H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01867-9 · Cited by 100
Weisberg, S. P., Carpenter, D. J., Chait, M., Dogra, P., Gartrell, R. D., Chen, A., Campbell, S., Liu, W., Saraf, P., Snyder, M. E., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.056 · Cited by 104
Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy
van Pul, K. M., Fransen, M. F., van de Ven, R., & de Gruijl, T. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643291 · Cited by 105
Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis
Shabaneh, T. B., Molodtsov, A. K., Steinberg, S. M., Zhang, P., Torres, G. M., Mohamed, G. A., Boni, A., Curiel, T. J., Angeles, C. V., & Turk, M. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0365 · Cited by 110
LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
Liu, Y., Debo, B. M., Li, M., Shi, Z., Sheng, W., & Shi, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-27179-7 · Cited by 109
Okoye, I., Houghton, M., Tyrrell, D. L., Barakat, K., & Elahi, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01215 · Cited by 105
Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy
Trefny, M. P., Kirchhammer, N., der Maur, P. A., Natoli, M., Schmid, D., Germann, M., Fernandez-Rodriguez, L., Herzig, P., Lötscher, J., Akrami, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35583-w · Cited by 98
The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview
Schaft, N. (2020) · Cancers · doi:10.3390/cancers12092567 · Cited by 100
Chung, H. K., McDonald, B., & Kaech, S. M. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201730 · Cited by 105
Cellular and molecular mechanisms of CD8(+) T cell differentiation, dysfunction and exhaustion
Verdon, D. J., Mulazzani, M., & Jenkins, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197357 · Cited by 98
The T cell differentiation landscape is shaped by tumour mutations in lung cancer
Ghorani, E., Reading, J. L., Henry, J. Y., de Massy, M. R., Rosenthal, R., Turati, V. A., Joshi, K., Furness, A. J. S., Aïssa, A. B., Saini, S. K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0066-y · Cited by 95
TCF-1: a maverick in T cell development and function
Gounari, F., & Khazaie, K. (2022) · Nature Immunology · doi:10.1038/s41590-022-01194-2 · Cited by 95
In vitro modeling of CD8 + T cell exhaustion enables CRISPR screening to reveal a role for BHLHE40
Wu, J. E., Manne, S., Ngiow, S. F., Baxter, A. E., Huang, H., Freilich, E., Clark, M. L., Lee, J. H., Chen, Z., Khan, O., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.ade3369 · Cited by 101
Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer
Rech, A. J., Balli, D., Mantero, A. M. A., Ishwaran, H., Nathanson, K. L., Stanger, B. Z., & Vonderheide, R. H. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0559 · Cited by 93
Precursors of exhausted T cells are pre-emptively formed in acute infection
Chu, T., Wu, M., Höllbacher, B., de Almeida, G. P., Wurmser, C., Berner, J., Donhauser, L. V., Gerullis, A.-K., Lin, S., Cepeda-Mayorga, J. D., et al. (2025) · Nature · doi:10.1038/s41586-024-08451-4 · Cited by 101
Wu, J., Zhang, H., Shi, X., Xiao, X., Fan, Y., Minze, L. J., Wang, J., Ghobrial, R. M., Xia, J., Sciammas, R., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.003 · Cited by 93
Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity
Qiu, Y., Su, Y., Xie, E., Cheng, H., Du, J., Xu, Y., Pan, X., Wang, Z., Chen, D. G., Hong, Z., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.11.003 · Cited by 98
Self-citationDeng, W., Lira, V., Hudson, T. E., Lemmens, E. E., Hanson, W. G., Flores, R., Barajas, G., Katibah, G. E., Desbien, A. L., Lauer, P., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801910115 · Cited by 91
Self-citationMita, Y., Kimura, M. Y., Hayashizaki, K., Koyama‐Nasu, R., Ito, T., Motohashi, S., Okamoto, Y., & Nakayama, T. (2018) · International Immunology · doi:10.1093/intimm/dxy050 · Cited by 92
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy
Bulliard, Y., Andersson, B. S., Baysal, M. A., Damiano, J. S., & Tsimberidou, A. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01504-7 · Cited by 98
Burrack, A. L., Spartz, E. J., Raynor, J. F., Wang, I., Olson, M. A., & Stromnes, I. M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.059 · Cited by 89
Mai, D., Johnson, O., Reff, J., Fan, T., Scholler, J., Sheppard, N. C., & June, C. H. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218632120 · Cited by 86
Resident memory T cells and cancer
Gavil, N. V., Cheng, K., & Masopust, D. (2024) · Immunity · doi:10.1016/j.immuni.2024.06.017 · Cited by 104
de Rodas, M. L., Villalba-Esparza, M., Sanmamed, M. F., Chen, L., Rimm, D. L., & Schalper, K. A. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00984-x · Cited by 98
Ibis, B., Aliazis, K., Cao, C., Yenyuwadee, S., & Boussiotis, V. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197364 · Cited by 92
Nair, R., Somasundaram, V., Kuriakose, A., Krishn, S. R., Raben, D., Salazar, R. L., & Nair, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548234 · Cited by 100
Jagodinsky, J. C., Vera, J. M., Jin, W. J., Shea, A. G., Clark, P. A., Sriramaneni, R. N., Havighurst, T. C., Chakravarthy, I., Allawi, R. H., Kim, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk0642 · Cited by 89
Regulators of CD8+ T cell exhaustion
Sun, Q., & Dong, C. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01221-x · Cited by 91
Tieu, R., Zeng, Q., Zhao, D., Zhang, G., Feizi, N., Manandhar, P., Williams, A. L., Popp, B. A., Wood, M. A., Demetris, A. J., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add8454 · Cited by 88
Cellular and molecular waypoints along the path of T cell exhaustion
Lan, X., Zebley, C. C., & Youngblood, B. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg3868 · Cited by 87
Stock, S., Übelhart, R., Schubert, M., Fan, F., He, B., Hoffmann, J., Wang, L., Wang, S., Gong, W., Neuber, B., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32201 · Cited by 82
Zhu, M., Han, Y., Gu, T., Wang, R. Y., Si, X., Kong, D., Zhao, P., Wang, X., Li, J., Zhai, X., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114065 · Cited by 90
Architects of immunity: How dendritic cells shape CD8 + T cell fate in cancer
Bhandarkar, V., Dinter, T., & Spranger, S. (2025) · Science Immunology · doi:10.1126/sciimmunol.adf4726 · Cited by 88
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade
Palmer, D. C., Webber, B. R., Patel, Y. K., Johnson, M. J., Kariya, C. M., Lahr, W. S., Parkhurst, M. R., Gartner, J. J., Prickett, T. D., Lowery, F. J., et al. (2022) · Med · doi:10.1016/j.medj.2022.07.008 · Cited by 82
Zhao, M., Kiernan, C. H., Stairiker, C. J., Hope, J. L., León, L. G., van Meurs, M., Brouwers-Haspels, I., Boers, R., Boers, J., Gribnau, J. H., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008555 · Cited by 81
Metabolic regulation of immunity in the tumor microenvironment
Li, S., Zhang, Y., Tong, H., Sun, H., Liao, H., Li, Q., & Ma, X. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116463 · Cited by 89
Bai, Y., Hu, M., Chen, Z., Wei, J., & Du, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.767070 · Cited by 74
Epigenetic strategies to boost CAR T cell therapy
Akbari, B., Ghahri-Saremi, N., Soltantoyeh, T., Hadjati, J., Ghassemi, S., & Mirzaei, H. R. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.003 · Cited by 79
Battistello, E., Hixon, K., Comstock, D. E., Collings, C. K., Chen, X., Rodriguez-Hernaez, J., Lee, S., Cervantes, K. S., Hinkley, M. M., Ntatsoulis, K., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.02.026 · Cited by 78
Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma
Zheng, C., Snow, B. E., Elia, A. J., Nechanitzky, R., Dominguez-Brauer, C., Liu, S., Tong, Y., Cox, M. A., Focaccia, E., Wakeham, A. C., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00624-w · Cited by 75
Guan, Y., Kraus, S. G., Quaney, M. J., Daniëls, M. A., Mitchem, J. B., & Teixeiro, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00586 · Cited by 76
Pillai, R., LeBoeuf, S. E., Hao, Y., New, C., Blum, J. L. E., Rashidfarrokhi, A., Huang, S. M., Bahamon, C., Wu, W., Karadal-Ferrena, B., et al. (2024) · Science Advances · doi:10.1126/sciadv.adm9859 · Cited by 81
Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 74
Understanding initiation and progression of hepatocellular carcinoma through single cell sequencing
Li, X., Shen, Y., Zhang, L., Guo, X., & Wu, J. H. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188720 · Cited by 73
Liu, M., Zhou, J., Chen, Z., & Cheng, A. S. L. (2016) · The Journal of Pathology · doi:10.1002/path.4832 · Cited by 69
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy
Ghoneim, H. E., Zamora, A. E., Thomas, P. G., & Youngblood, B. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.10.002 · Cited by 71
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis
Gorini, F., Azzimonti, L., Delfanti, G., Scarfò, L., Scielzo, C., Bertilaccio, M. T. S., Ranghetti, P., Gulino, A., Doglioni, C., Napoli, A. D., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751065 · Cited by 71
Carmona, S. J., Siddiqui, I., Bilous, M., Held, W., & Gfeller, D. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1737369 · Cited by 69
Allie, S. R., & Randall, T. D. (2020) · Viral Immunology · doi:10.1089/vim.2019.0141 · Cited by 73
Exhausted T cells and epigenetic status
Zeng, Z., Wei, F., & Ren, X. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0338 · Cited by 73
Roussel, M., Le, K.-S., Granier, C., Gutierrez, F. L., Foucher, E. D., Gallou, S. L., Pangault, C., Xerri, L., Launay, V., Lamy, T., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003080 · Cited by 72
Wang, X., Chen, Y., Li, Z., Huang, B., Xu, L., Lai, J., Lu, Y., Zha, X., Liu, B., Lan, Y., et al. (2021) · Advanced Science · doi:10.1002/advs.202101447 · Cited by 71
Dolina, J. S., Lee, J., Brightman, S. E., McArdle, S., Hall, S. M., Thota, R. R., Zavala, K. S., Lanka, M., Premlal, A. L. R., Greenbaum, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164258 · Cited by 68
Chen, J., Song, Y., Miao, F., Chen, G., Zhu, Y., Wu, N., Pang, L., Chen, Z., & Chen, X. (2021) · Cancer Science · doi:10.1111/cas.15033 · Cited by 70
Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity
Garrido, G., Schrand, B., Rabasa, A., Levay, A. K., D’Eramo, F., Berezhnoy, A., Modi, S., Gefen, T., Marijt, K. A., Doorduijn, E. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11728-2 · Cited by 69
The CD112R/CD112 axis: a breakthrough in cancer immunotherapy
Zeng, T., Cao, Y., Jin, T., Tian, Y., Dai, C., & Xu, F. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02053-y · Cited by 72
Shao, M., Teng, X., Guo, X., Zhang, H., Huang, Y., Cui, J., Si, X., Ding, L., Wang, X., Li, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202103508 · Cited by 67
Li, X., Wang, R., Fan, P., Yao, X., Qin, L., Peng, Y., Ma, M., Asley, N., Chang, X., Feng, Y., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01066 · Cited by 68
DCision-making in tumors governs T cell anti-tumor immunity
Alfei, F., Ho, P., & Lo, W. (2021) · Oncogene · doi:10.1038/s41388-021-01946-8 · Cited by 68
Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models
Si, X., Xiao, L., Brown, C. E., & Wang, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063154 · Cited by 70
Tu, W. J., McCuaig, R., Tan, A. H. Y., Hardy, K., Seddiki, N., Ali, S. S., Dahlstrom, J. E., Bean, E. G., Dunn, J., Forwood, J. K., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01228 · Cited by 67
Unraveling exhaustion in adaptive and conventional NK cells
Merino, A. M., Kim, H., Miller, J. S., & Cichocki, F. M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.4mr0620-091r · Cited by 65
Ahn, T., Bae, E., & Seo, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.004 · Cited by 71
Hu, H., Zakharov, P. N., Peterson, O. J., & Unanue, E. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019743117 · Cited by 63
Proteotoxic stress response drives T cell exhaustion and immune evasion
Wang, Y., Ma, A., Song, N.-J., Shannon, A. E., Amankwah, Y. S., Chen, X., Wu, W., Wang, Z., Saadey, A. A., Yousif, A., et al. (2025) · Nature · doi:10.1038/s41586-025-09539-1 · Cited by 68
Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy
Borst, J. G., Busselaar, J., Bosma, D. M. T., & OSSENDORP, F. A. (2021) · European Journal of Immunology · doi:10.1002/eji.202048994 · Cited by 66
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
Nixdorf, D., Sponheimer, M., Berghammer, D., Engert, F., Bader, U., Philipp, N., Pasikhani, M. K., Straub, T., Rohrbacher, L., Wange, L. E., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01905-0 · Cited by 63
Targets of tumor microenvironment for potential drug development
Zhang, L., Wang, Z., Liu, K., Liu, Y., Wang, S., Jiang, W., Lu, F., & Dang, Y. (2024) · MedComm – Oncology · doi:10.1002/mog2.68 · Cited by 68
Dammeijer, F. F., Lau, S. P., van Eijck, C. H. J., van der Burg, S. H., & Aerts, J. G. J. V. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.011 · Cited by 66
Metadata
- Authors
- Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., Schell, T. D., Garbi, N., & Greenberg, P. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Aduro BioTech (United States) (US)
- German Cancer Research Center (DE)
- Pennsylvania State University (US)
- University of Bonn (DE)
- Corresponding author
- Schietinger, Andrea
- Greenberg, Philip D.
- ORCID
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 45
- Issue
- 2
- Pages
- 389-401
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC5119632
- OpenAlex
- W2514996992
- Cited by
- 720
- References
- 60
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 93 · 2023: 84 · 2022: 78 · 2021: 103 · 2020: 99 · 2019: 61 · 2018: 50 · 2017: 25 · 2016: 5
- FWCI
- 25.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R00CA172371, K99CA172371, K08CA158069, R01CA033084, P30CA008748, P30CA015704)
- National Institute of Allergy and Infectious Diseases (R21AI107776)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-specific T cells, CD8+ T cell dysfunction, carcinogenesis, SV40 large T antigen, liver cancer, T cell differentiation, T cell exhaustion, cancer immunotherapy
- MeSH terms
- Animals, Antigens, Polyomavirus Transforming, Cell Differentiation, Cells, Cultured, Disease Models, Animal, Humans, Liver Neoplasms, Lymphocyte Activation, Mice, Inbred C57BL, Mice, Transgenic, Tamoxifen, Immunotherapy, Adoptive, Cellular Senescence, CD8-Positive T-Lymphocytes, Cancer Vaccines, Mice, Tumor Microenvironment, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
